Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program

E. S. Kim,Roy S. Herbst,J. J. Lee,George R. Blumenschein,A. Tsao,Ignacio Ivan Wistuba,Christine M. Alden,S. Gupta,David J. Stewart,Waun Ki Hong

Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program

2009

E. S. Kim
Roy S. Herbst
J. J. Lee
George R. Blumenschein
A. Tsao
Ignacio Ivan Wistuba
Christine M. Alden
S. Gupta
David J. Stewart
Waun Ki Hong

8024 Background: Treatment for patients (pts) with recurrent NSCLC has limited efficacy despite the use of new targeted agents. Identifying biomarkers to predict tumor response will help personaliz...

Keywords:

Clinical trial
non-small cell lung cancer (NSCLC)
Targeted therapy
Randomized controlled trial
Biomarker (medicine)
Lung cancer
Pathology
Medicine
Oncology
Recurrent NSCLC
Internal medicine
tumor response

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations